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This review summarizes the current state-of-the-art regarding the endovascular management of acute
ischemic stroke. Beginning with intravenous tissue plasminogen activator, this paper traces the gradual
shift of systemic thrombolysis from a competing to complementary treatment modality. Intra-arterial
thrombolysis, mechanical thrombectomy with the Merci (Concentric Medical, Mountain View, California)
and Penumbra (Penumbra, Inc., Alameda, California) systems, angioplasty, primary intracranial stenting,
and emerging stentriever devices are sequentially reviewed. Ultimately, this paper lays the foundation
for current endovascular stroke management and considers future areas of progress and research.
(J Am Coll Cardiol Intv 2011;4:261–9) © 2011 by the American College of Cardiology FoundationStroke Epidemiology
Acute ischemic stroke inflicts tremendous morbid-
ity and mortality. In the United States, 795,000
new and recurrent strokes occur annually, with
direct economic costs in excess of $73 billion (1).
Over the past decade, mechanical thrombectomy
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262stroke. This paper reviews the data underpinning recent
progress in the endovascular management of ischemic stroke
and ranges from IV t-PA to the advent of stentriever devices.
Patient Selection
Important features of the patient’s clinical presentation that
bear on endovascular treatment decisions include the follow-
ing: 1) time since onset of ictus; 2)
severity of neurologic deficit
quantified by the National Insti-
tutes of Health Stroke Scale
(NIHSS) (2); 3) age (2); 4) base-
line functional status; 5) features
of medical history that suggest a
potential stroke etiology; and 6)
vascular anatomy.
Presentation within 4.5 h of-
fers the patient the possibility
of IV t-PA as a definitive ther-
apy or bridge to endovascular
intervention (3). Wake-up strokes
require the conservative assump-
tion that the ictus coincides with
the time that the patient was last
seen in a normal state. However,
physiologic imaging modalities
mitigate against this clinical un-
certainty and allow meaningful
intervention in select patients
beyond 8 h with good clinical
outcomes (4).
Patients with an NIHSS score
8 or5 with a substantial apha-
sic component receive screening
for endovascular intervention.
Age and functional status serve as
complementary elements of stroke
patient evaluation. Generally
speaking, patients older than 80
years of age fare more poorly with
endovascular therapy, with in-
creasing risks of poor functional
outcome and iatrogenic hemor-
rhage (2). Independent functional
status may ultimately qualify pa-
tients older than 80 years of age
or endovascular evaluation.
After completion of an expedited clinical evaluation, the
atient proceeds to noninvasive imaging. At Millard Fill-
ore Gates Hospital at the University at Buffalo, the
omputed tomography (CT) imaging stroke protocol in-
ludes: 1) a noncontrast cranial CT scan to exclude hemor-
Abbreviations
and Acronyms
CBF  cerebral blood flow
CBV  cerebral blood
volume
CT  computed tomography
CTP  computed
tomography perfusion
FDA  U.S. Food and Drug
Administration
IA  intra-arterial
ICH  intracerebral
hemorrhage
IMS  Interventional
Management of Stroke
IV  intravenous
MCA  middle cerebral
artery
mRS  modified Rankin
scale
NIHSS  National Institutes
of Health Stroke Scale
NINDS  National Institute
of Neurological Disorders
and Stroke
OR  odds ratio
r-proUK  recombinant
pro-urokinase
rt-PA  recombinant tissue
plasminogen activator
TCD  transcranial Doppler
TIBI  Thrombolysis in
Brain Ischemia
TIMI  Thrombolysis In
Myocardial Infarction
t-PA  tissue plasminogen
activator
UK  urokinasehagic conversion or other structural abnormality; 2) CT uerfusion (CTP) imaging with special attention to time-to-
eak, cerebral blood flow (CBF), and cerebral blood volume
CBV) sequences; and 3) CT angiography of the aortic arch
hrough the intracranial vessels. Perfusion imaging is per-
ormed on a 320-slice Aquilon scanner (Toshiba Medical
ystems, Tustin, California).
CTP is being evaluated for the assessment of a completed
nfarct in the vascular distribution of the occluded vessel and
stimation of the tissue at risk of becoming an infarct if not
eperfused. Perfusion features stratify the patient’s risk of hem-
rrhage after endovascular intervention and potential benefit of
echanical flow restoration. In general terms, when decreased
BF and CBV (findings suggestive of a completed infarct)
epresent less than one third of the territory exhibiting
ncreased time-to-peak (putative penumbra), we have found
hat the patient benefits from endovascular intervention and
as a lower risk of symptomatic intracerebral hemorrhage
ICH). Early ischemic changes on a noncontrast CT scan
hat correspond to CBF and CBV deficits solidify the
eliability of predicting a completed infarct. Reperfusion of
larger necrotic core is ineffective and would likely increase
he risk of hemorrhage (5). Conversely, patients with
yperacute presentations (i.e., 2 h) were found to have
alvageable of regions with decreased CBV and CBF after
ndovascular therapy, even in the face of a poor CTP
rofile. Finally, occlusion of proximal M1 perforators and
ttendant basal ganglionic involvement in the infarct core
resaged a higher risk of hemorrhage after recanalization
nd poor clinical outcome (6). The main limitation of CTP
n our experience has been that it lacks the ability to
ccurately differentiate between true penumbra (tissue that
ill be converted to an infarct if it is not reperfused) and
enign oligemia (tissue that is ischemic when compared
ith surrounding tissue but will survive due to collaterals
ven if not reperfused). Recent studies suggest that clinical
mprovement is noted even in late reperfusion patients with
arge penumbras identified on CTP imaging (4,7). We must
mphasize here that the use of CTP as an aid in selecting
atients for endovascular therapy is at present purely exper-
mental, and the lessons that we have learned and the measures
hat we use at our institution need to be studied as part of
multicenter, randomized, prospective, controlled trial.
Recently, there has been interest in estimating CTP
hresholds and using quantitative and automated CTP maps
o estimate core and penumbra to aid in choosing patients
or reperfusion beyond traditional therapeutic windows or
hen time of onset of stroke is not known (8,9). Differences
n CTP hardware and software can affect quantified metrics
10,11), and clearly defined thresholds for guiding therapy
ave yet to be standardized (12). Some studies suggest the
se of CBF thresholds for defining areas of infarct, specif-
cally CBF 25 ml/100 g/min (13). In an analysis of 130
atients with acute stroke, Wintermark et al. (14) suggested
sing absolute CBV2 ml/100 g to define core infarct, and
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263a relative mean transit time increase 145% of normal to
define penumbra. Murphy et al. (13) studied 30 patients and
demonstrated CBF  CBV as the best predictor for differ-
entiating core infarct and penumbra, better than CBF or
CBV thresholds alone. Specific thresholds are also specific to
the perfusion software platform being used and may not be
automatically transferable to other vendors, scanners, and
even software versions. At this time, much work remains to
standardize quantitative methods of CTP interpretation,
which, in the future, may be addressed by a proposed
consortium for acute stroke imaging (12).
Attention should be paid to technical aspects of data
acquisition and post-processing, including placement of
regions of interest and selecting an appropriate volume of
imaging for the patient’s clinical syndrome (15). Entities
such as chronic infarct, severe microvascular ischemia, and
seizure can be mistaken for acute infarct. Vascular stenoses
can mimic and overestimate areas of ischemic penumbra;
therefore, CTP should always be performed and interpreted
in conjunction with CT angiography (5).
CT angiography, although not essential at institutions
proceeding directly to the performance of catheter angiog-
raphy for diagnostic purposes, provides critical information
for endovascular planning. First and foremost, the target
vessel occlusion (identified mostly by clinical correlation
with symptoms) responsible for the patient’s presentation is
confirmed with the corresponding CTP data. Additionally,
CT angiography allows us to determine the length of the
occlusion, identify the presence of tandem occlusions, and
plan macrovascular access.
IV Thrombolysis
In acute ischemic stroke, IV thrombolytic therapy remains
the standard of care for qualifying patients (16). In 1996,
the U.S. Food and Drug Administration (FDA) ap-
proved the use of IV recombinant tissue plasminogen
activator (rt-PA), based largely on the results of the
National Institute of Neurological Disorders and Stroke
(NINDS) rt-PA Stroke Study (17). In 2008, the Euro-
pean Cooperative Acute Stroke Study III trial (3) dem-
onstrated a statistically significant benefit of IV t-PA
administered within the 3- to 4.5-h treatment window. The
DEFUSE (Diffusion and perfusion imaging Evaluation For
Understanding Stroke Evolution) study evaluated 74 pa-
tients with a perfusion-diffusion mismatch on magnetic
resonance imaging as a surrogate for ischemic penumbra
(18). The assumption was that these patients would benefit
from IV thrombolysis in an extended time window of 3 to
6 h after onset. A target-mismatch profile was defined as a
perfusion-weighted imaging lesion that was 10 ml and
120% of the diffusion-weighted imaging lesion without a
malignant profile; a malignant profile was defined as a
baseline diffusion-weighted imaging lesion 100 ml and/ora perfusion-weighted imaging lesion of 100 ml. Early
reperfusion was associated with favorable clinical response
in patients with a perfusion-diffusion mismatch (odds ratio
[OR]: 5.4; p  0.039) and an even more favorable response
in patients with the target-mismatch profile (OR: 8.7; p 
.011). Patients with the no-mismatch profile (i.e.,
erfusion-weighted imaging corresponded to diffusion-
eighted imaging) did not appear to benefit from early
eperfusion. In patients with the malignant profile, early
eperfusion was associated with 50% symptomatic ICH.
arly reperfusion was associated with symptomatic ICH in
0% of patients with the malignant profile compared with
.7% with the target-mismatch profile. This study sug-
ested that perfusion imaging may stratify patients who
tand to benefit from IV thrombolysis during a 3- to 6-h
indow versus patients for whom IV t-PA presents a higher
emorrhagic risk.
The technical success of IV t-PA in achieving revascu-
arization was well characterized by a study using transcra-
ial Doppler (TCD) imaging. In 109 patients, TCD imag-
ng allowed classification of waveforms into Thrombolysis
n Brain Ischemia (TIBI) tiers (19). The recanalization
TIBI 4 or 5) rate was 35% for patients who presented with
inimal to no initial flow (TIBI 0 or 1) and 52% for
atients with initial partial occlusion (TIBI 2 or 3). TIBI
ow recovery correlated with NIHSS score improvement;
echnical outcomes, therefore, corresponded to clinical re-
ults. At 24-h, NIHSS scores were higher in patients with
IBI flow grade 0 or 1 than those with TIBI flow grade 4
r 5. Lack of flow recovery predicted worsening or lack of
mprovement and a high mortality rate (71%) for patients
ith posterior circulation occlusions. Additional TCD stud-
es supported the need for adjunctive methods in cases of
ailed IV t-PA revascularization (20,21). In large-vessel
cclusive strokes, a high percentage of vessels did not
ompletely recanalize after IV thrombolysis. Failed revascu-
arization rates corresponded to the occlusion site: 67%
iddle cerebral artery (MCA), 25% basilar artery, and 100%
nternal carotid artery (Thrombolysis In Myocardial Infarc-
ion [TIMI] [22] flow grades 0 to 2); this correlated with
ignificant neurologic deficits at 24 h (20,21).
ntra-Arterial (IA) Thrombolysis
Although IV thrombolysis represents the standard of care
for eligible patients and t-PA is the only drug to receive
FDA approval for treatment of ischemic stroke, it offers
only marginal efficacy in large-vessel occlusions. Overall, in
most cases, IV t-PA–induced recanalization occurs during
the first hour after treatment (complete in 31% and partial
in 22%), by TCD monitoring. The probability of recanali-
zation after the first 60 min drops significantly (OR for
delayed/early recanalization: 0.16 [95% confidence interval:
0.085 to 0.304; p  0.001]) (23).
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264Theoretically, IA thrombolysis may offer a higher dose of
thrombolytic drug delivery to the clot with fewer systemic
complications and higher recanalization rates (24). IA
treatment may also facilitate extension of the therapeutic
window and provide an option for patients with contrain-
dications to systemic thrombolysis (i.e., postoperative
stroke) or patients in whom IV thrombolysis has failed.
ngiographic precision confers the following advantages:
) gold standard characterization of the obstructive le-
ion; 2) imaging of collateral flow anatomy; 3) confirma-
ion and exact degree and timing of recanalization; and
) combination with mechanical thrombectomy methods.
onversely, disadvantages of IA treatment include delay in
reatment, risks of catheter manipulation, and the need for
killed endovascular facilities and personnel (24).
The PROACT (Prolyse in Acute Cerebral Thromboem-
olism) studies evaluated IA thrombolysis with recombinant
ro-urokinase (r-proUK) in patients within 6 h of an MCA
M1 or M2 segment) occlusion stroke (25,26). The
PROACT-II study (a phase III prospective, randomized,
placebo-controlled study) enrolled 180 patients with a
median NIHSS score of 17 (range 4 to 30) (26). A favorable
outcome (modified Rankin scale [mRS] score of 0 to 2 at 90
days) was achieved in 40% of patients treated with IA
r-proUK (9 mg; plus low-dose heparin) versus only 25% of
control subjects (low-dose heparin only) (p  0.04). The
recanalization rate was significantly higher in the r-proUK
group (66%) than in the control group (18%) (p  0.001).
lthough the symptomatic ICH rate was higher in r-proUK
atients (10%) than in control patients (2%) (p  0.06), no
difference in mortality rate was observed. Although only IA
r-proUK was used in the PROACT study of thrombolysis
because of the unavailability of this drug, rt-PA is used for
IA thrombolysis (r-proUK was used in PROACT but is not
available at present, so rt-PA is used). However, the FDA
has not yet approved rt-PA for IA thrombolysis.
Two studies in Japan evaluated IA-UK treatment. Using
data from Japan’s J-MUSIC (Multicenter Stroke Investiga-
tor’s Collaboration), an initial case-control analysis assessed
the effects of IA-UK thrombolysis in 91 patients with acute
cardioembolic stroke and presentation NIHSS score of 5 to
22 (median NIHSS score, 14) who were treated within
4.5 h of symptom onset (27). Favorable outcomes (mRS
score of 0 to 2) occurred in 50.5% of the UK group and
34.1% of the control group (p  0.0124), with no differ-
ences in mortality rate.
The MELT (Middle Cerebral Artery Embolism Local
Fibrinolytic Intervention Trial) represents the second Japa-
nese study (28). Approval of IV infusion of rt-PA in Japan
prompted early termination of this trial. This randomized
trial enrolled 57 patients to IA-UK versus 57 patients to
placebo within 6 h of MCA (M1 or M2 segment) stroke.
No significant advantages were observed for IA treatmentwith respect to favorable outcome (mRS score of 0 to 2) at
90 days. Excellent functional outcomes at 90 days (mRS
score of 0 to 1) were present in 42.1% of the IA group and
in 22.8% of the placebo group (p  0.045; OR: 2.46, 95%
onfidence interval: 1.09 to 5.54), with a significantly higher
ncidence of NIHSS 0 to 1 scores in the IA group compared
ith the control group (p  0.017). No significant differ-
nce was observed in mortality or ICH rate.
From these Japanese IA thrombolysis studies, it is
pparent that the recanalization rate may differ with
cclusion site and stroke etiology. Consideration of the
cclusion pathology may therefore inform endovascular
lanning. Lower recanalization rates were observed in pa-
ients with thromboembolic carotid-terminus occlusion
30%) relative to MCA M1-segment (50%) or M2-segment
90%) occlusions (29).
A retrospective study of 62 patients treated with IA-UK
ithin 6 h of stroke onset evaluated whether recanalization
iffers among different types of thromboembolic occlusions
29). Treatment of carotid territory occlusions resulted in an
verall 53% recanalization efficacy: 28% of carotid-terminus,
5% of M1-segment, 74% of distal M1-segment, and 60%
f M2-segment occlusions. Regression analysis revealed
hat only the recanalization rate correlated with occlusion
ite (p  0.010). The recanalization rate was not influenced
y stroke etiology (large-artery atherosclerosis, cardioembo-
ism without transesophageal echocardiography findings, or
troke of undetermined etiology); a subgroup of patients
ith cardiac thrombus confirmed by transesophageal echo-
ardiography had significantly lower recanalization rates and
ere the lone exception (p  0.017). In summary, IA
ecanalization success of thromboembolic carotid territory
cclusions corresponded to thromboembolus location but
ot stroke etiology.
ombined IV and IA Thrombolysis
The IMS (Interventional Management of Stroke) studies
aimed to investigate the feasibility and safety of a combined
IV and IA approach to thrombolysis. In IMS-I, 80 patients
were enrolled within 3 h of stroke onset; the median
baseline NIHSS score was 18 (30). The patients received IV
t-PA at 0.6 mg/kg followed by 22 mg IA via a 2-h infusion
or until thrombolysis. Outcome was compared with that in
the NINDS rt-PA stroke trial (17). IMS subjects had a
significantly better outcome at 3 months than NINDS
placebo-treated subjects for all outcome measures (OR:2)
but not beyond the benefit conferred to the IV thrombolysis
group.
IMS-II was a continuous, nonrandomized, safety and
feasibility pilot study to evaluate the efficacy and safety of
reduced-dose IV rt-PA (0.6 mg/kg), followed by IA rt-PA
coupled with low-energy sonography to theoretically in-
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265crease fluid permeation and thrombolytic infusion within
the clot (via the EKOS Primo Micro-Infusion Catheter
[EKOS Corporation, Bothell, Washington]) (31). IMS-II
subjects had significantly better outcomes at 3 months than
NINDS placebo-treated subjects for all end points (OR:
2.7) and better outcomes than NINDS rt-PA–treated
subjects as measured by the Barthel Index and Global
Outcome Test.
Pooled IMS I and II data showed that partial or complete
recanalization occurred in 74.6% of internal carotid artery–
terminus and MCA-M1 occlusions, with good reperfusion
(Thrombolysis In Myocardial Infarction [TIMI] flow grade
2/3) in 61.3% (31,32). Revascularization correlated strongly
with good outcome for TIMI flow grade 2 or 3 reperfusion
(p  0.0004). Compared with the NINDS t-PA stroke
rial, 3-month mortality was nonsignificantly lower in
MS-II (16%) compared with placebo-treated patients
24%) or rt-PA–treated patients (21%). The rate of symp-
omatic ICH was higher in IMS-II (9.9%) but not signif-
cantly different from that in the NINDS t-PA stroke trial
6.6%). The definitive trial, IMS-III, is ongoing, and the
esults will likely provide class I evidence of the concept of
V-IA therapy.
echanical Thrombectomy
IV t-PA results in early recanalization in only 30% to 50%
of patients, with even lower rates of revascularization in
larger vessel occlusions and is associated with a reocclusion
rate as high as 17% (33–36). Mechanical revascularization
for acute stroke may be considered for intracranial large-
vessel occlusions in patients presenting with acute stroke.
Clot perturbation may be achieved with common devices
such as microwires, snares, and angioplasty balloons, al-
though these techniques have not been evaluated in pro-
spective trials.
Two FDA-approved devices are available specifically for
mechanical thrombectomy: the Merci retriever (Concentric
Medical, Mountain View, California) and the Penumbra
(Penumbra, Inc., Alameda, California). The Merci re-
triever, FDA approved in 2004, is a corkscrew-shaped
device consisting of a flexible nitinol wire in 5 helical loops.
Designed for placement distal to the thrombus, retrieval
allows en bloc thrombus removal (Fig. 1). The penumbra
device (Fig. 2), by contrast, works proximally to disrupt and
aspirate the thrombus. Both devices are designed for throm-
bectomy in carefully selected acute stroke patients with
large-vessel intracranial occlusions.
The MERCI (Mechanical Embolus Removal in Cerebral
Ischemia) and Multi-MERCI trials evaluated the safety and
efficacy in the setting of acute stroke within 8 h of onset
(37–39). The primary end points were successful revascu-
larization in all treatable vessels and major device-relatedcomplications. The control arm was the spontaneous recan-
alization rate of 18% from the PROACT II (26) trial. In the
Multi-MERCI Part I, 111 patients with an average baseline
NIHSS score of 19 underwent thrombectomy with the
newer generation L5 retriever device (37). Thirty patients
received IV t-PA before intervention. Treatment with the
retriever alone resulted in revascularization in 60 of 111
vessel (54%) and in 77 of 111 vessels (69%) after additional
therapy (IA t-PA, mechanical clot disruption). Ten of 111
patients (9.0%) had a symptomatic ICH; of these 10 patients,
2 received IV t-PA and 8 did not. The rate of clinically
significant device-related complications was 4.5%. Among
patients in whom revascularization was achieved, there was
a 2-fold survival advantage, and a significantly higher
proportion of patients lived without significant disability.
Multi-MERCI Part II included an additional 52 patients
with 3-month outcome of 39% of patients with an mRS
score of2, symptomatic ICH rate of 7.99%, asymptomatic
ICH rate of 28.9%, and mortality in 30% (38). This trial
was important in establishing that mechanical thrombec-
tomy could be safely and effectively performed in patients
who received IV t-PA as well as those who are not
candidates for IV thrombolytic agents.
The integral components of the Merci Retrieval System
include the Merci retriever, Merci microcatheter, and the
Merci balloon guide catheter (balloon guide). The Merci
procedure is performed after femoral artery access is ob-
tained with the Merci balloon guide, which comes in both
8- and 9-F outer diameters. Once the balloon guide is in the
conduit vessel of interest, a medium-sized catheter (4.2- and
5.3-F outer diameters), the distal access catheter (used for
triaxial support), and microcatheter of choice are advanced
over the microwire to the clot under direct fluoroscopic
guidance. The microwire is then exchanged for the Merci
retriever system with placement distal to the clot (Fig. 3).
The balloon guide is then inflated. Using a slow, steady
pulling motion, the retriever engages the clot while the
Figure 1. The Merci Retriever
The Merci retriever is a corkscrew-shaped device that consists of a ﬂexible
nitinol wire in 5 helical loops (courtesy of Concentric Medical, Mountain
View, California).distal access catheter position is maintained. Then, as the
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266clot moves more proximally, the distal access catheter,
microcatheter, and retriever are moved toward the guide while
aggressive aspiration is performed from the guide. The
retriever can be resheathed and the steps repeated.
The Penumbra Pivotal Stroke Trial also showed that
the Penumbra device was safe and effective for revascu-
larization in patients with acute intracranial large-vessel
occlusion (40). This prospective, multicenter, single-arm
study included 125 patients with an NIHSS score of at
least 8, presenting within 8 h of symptom onset, and
ineligible for or with an occlusion refractory to IV t-PA.
TIMI flow grade 2 or 3 revascularization was obtained in
81.6% of patients. ICH was seen in 28% of patients, 11%
of whom were symptomatic. Overall mortality was 32.8%
from all causes.
The Penumbra system has 3 main components: a reperfu-
sion catheter, separator, and a thrombus removal ring. The
Penumbra procedure is performed after arterial access is
obtained and usually after systemic heparinization. All
components of the Penumbra system are deliverable
through a 6-F standard guide catheter, but an 070 Neuron
catheter (Penumbra, Inc.) is the guide designed for the
system. The reperfusion catheter is then advanced past the
guide catheter over a guidewire and placed proximal to the
clot. The catheters and separators are available in different
Figure 2. Penumbra Thrombus Perturbation and Aspiration System
(Top) Schematic representation. (Bottom) Model of Penumbra aspiration
catheter and separator proximal to intraluminal thrombus (courtesy of Pen-
umbra, Inc., Alameda, California).sizes for various arterial diameters (Fig. 4). The guidewire isthen removed from the reperfusion catheter, and the pen-
umbra separator is advanced through the reperfusion cath-
eter. The aspiration pump is then started and a continuous
aspiration, clot disruption-debulking process is performed
with the separator. In general, the Penumbra device works
better in straight arterial segments than around curves or at
branch points because the separator may cause arterial
perforation. In addition, the largest catheter possible should
be used to allow for the greatest amount of aspiration
because suction decreases dramatically with decreasing ves-
sel diameter.
In general, mechanical thrombectomy has been proven
safe and effective for removal of clots in large vessels after
acute ischemic stroke in multiple nonrandomized, prospec-
tive trials. Mechanical thrombectomy requires the knowl-
edge and skills of trained neurointerventionists with expe-
rience in the use of these devices who can choose patients
best suited for this treatment.
Figure 3. The Merci Retriever
The device is placed distal to the clot (top), engages the clot (middle), and
then pulls the clot back into the guide catheter (bottom) (courtesy of Con-
centric Medical).
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267Stent-Assisted Revascularization for
Acute Ischemic Stroke
Several retrospective case series reported successful use of
self-expanding stents for acute stroke treatment, with higher
rates of recanalization than those obtained with other
recanalization modalities (41–43). A multicenter retrospec-
tive review of prospectively collected data for 20 acute
ischemic stroke patients (mean presentation NIHSS score
of 17) treated with Enterprise stent (Codman Neurovascu-
lar, Raynham, Massachusetts) placement as a bail-out pro-
cedure after current embolectomy options had been used
showed TIMI flow grade 2 or 3 recanalization in all patients
(100%) and improvement in NIHSS score of 4 points at
discharge in 75% of patients (44). Adjunctive therapy
included Merci retrieval (n  12), angioplasty (n  7),
glycoprotein IIb/IIIa inhibition (n  12), IA nitroglycerin
administration (n  1), Wingspan stent (Boston Scientific,
Natick, Massachusetts) deployment (n  3), and Xpert
stent (Abbott Laboratories, Abbott Park, Illinois) deploy-
ment (n  1). The authors found that the Enterprise stent
could be more easily navigated and deployed to the occlu-
sion site than the Wingspan stent, attested by its use in 3
cases of failed Wingspan stenting.
On the basis of these preliminary data, we received FDA
approval for a pilot study, SARIS (Stent-Assisted Recana-
lization in acute Ischemic Stroke), to evaluate the Wingspan
stent for revascularization in patients who did not improve
after or had a contraindication to IV thrombolysis (45). The
mean time interval from stroke onset to intervention was 5 h
13 min. Total time from procedure onset to vessel recana-
lization was 45 min. The average presenting NIHSS score
was 14. Seventeen patients presented with a TIMI score of
0 and 3 patients with a TIMI score of 1. Occluded vessels
included the right MCA (n  11), left MCA (n  5), basilar
Figure 4. The Penumbra Aspiration System
Shown are matching catheters and separators 041, 032, and 026 (courtesy
of Penumbra, Inc.).artery (n 3), and right carotid terminus (n 1). Intracranialtents were placed in 19 of 20 enrolled patients. One patient
xperienced recanalization of the occluded vessel with po-
itioning of the Wingspan stent delivery system before stent
eployment. In 2 patients, the tortuous vessel did not allow
racking of the Wingspan stent. The more navigable Cordis
nterprise stent (Cordis Neurovascular, Inc., Miami Lakes,
lorida) was used in both these cases. Twelve patients had
ther adjunctive therapies: IA eptifibatide (n  10), IA
t-PA (n  2), angioplasty (n  8), and IV rt-PA (n  2).
TIMI flow grade 2 or 3 recanalization was achieved in 100%
of patients; 65% of patients improved 4 points in the
NIHSS score after treatment. One patient (5%) had symp-
tomatic ICH and 2 had asymptomatic ICH. At the
1-month follow-up evaluation, 12 of 20 patients (60%) had
a mRS score of 2 and 9 (45%) had an mRS score of 1.
Mortality at 1 month was 25% (n 5). None of the patients
nrolled in this study died due to any cause related to stent
lacement; all deaths were due to the severity of the initial
troke and associated comorbidities.
tent-Assisted Revascularization: Durability,
ate Outcomes, and the Rise of Stentrievers
The main limitation of current stent-assisted revasculariza-
tion, as reported in the literature, is the theoretical risk of
acute and mid-term stent failure (within 6 months of stent
deployment), based on the Wingspan registries. Currently,
there are no large studies that assess stent patency and
complications related to placement of a permanent implant
in an acute ischemic stroke patient beyond 1 month of stent
placement. Mid-term results from SARIS are currently
under review. Zaidat et al. (42) reported 1 case (11%) of
immediate in-stent restenosis after acute stroke treat-
ment. The risk of in-stent stenosis may be higher in the
setting of symptomatic intracranial stenosis or acute
stroke compared with the “natural history” of intracranial
stents placed for other pathologic indications, such as
aneurysm treatment (46).
The need for aggressive antiplatelet and/or anticoagulant
therapy associated with intracranial stent placement (42,47–53)
is a second major disadvantage if stent placement is used as a
treatment technique in the setting of acute stroke. Zaidat et al.
(42) reported an 11% hemorrhage rate associated with stent
placement for acute stroke. Moreover, Levy et al. (41) reported
an identical 11% incidence of lethal hemorrhages in patients
treated with stent placement for acute stroke.
Stentriever designs attempt to maintain the advantages of
a stent platform, namely, navigability, fast device delivery,
and quick flow restoration, without condemning the patient
to the disadvantages of a permanent intracranial implant.
We have reported the feasibility of using the Solitaire FR
device (ev3, Irvine, California; now Covidien Vascular Ther-
apies, Mansfield, Massachusetts) in a canine stroke model
with soft and hard clots in the intracranial circulation
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268(Fig. 5) (54). Current ongoing clinical trials include SWIFT
(Solitaire FR With the Intention For Thrombectomy), a
multicenter study to test the safety and efficacy of the
Solitaire FR stent platform based clot retriever and compare
it with the FDA-approved Merci clot retriever, and SARIS-
II, a study of another 20 prospective patients treated with
Wingspan stent–assisted recanalization for stroke.
Conclusions
Tremendous progress in the endovascular management of
acute ischemic stroke lends great optimism to ongoing
research efforts. As perfusion imaging and technical ad-
vancements in mechanical thrombectomy expand the num-
ber of candidates for meaningful endovascular intervention,
it becomes our collective responsibility to ensure patient
access to these advancements. Although much work remains
to prospectively validate the results presented in this paper,
momentum in the field augurs the prospect of continued
advancement.
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Figure 5. The Solitaire FR Device
Solitaire FR device (ev3, Irvine, California; now Covidien Vascular Therapies,
Mansﬁeld, Massachusetts). Device with retrieved clot. Reprinted, with per-
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